Getting Histoplasmosis on the Map of International Recommendations for Patients with Advanced HIV Disease

Area of Science:

• Mycology
• Infectious Diseases
• Public Health

Background:

• Progressive disseminated histoplasmosis, caused by H. capsulatum, is a severe, AIDS-defining opportunistic infection.
• It is frequently under-diagnosed or misdiagnosed, leading to fatal outcomes, with an estimated global burden exceeding 100,000 cases.
• Histoplasmosis is a significant cause of mortality in individuals with Acquired Immunodeficiency Syndrome (AIDS).

Purpose of the Study:

• To highlight the critical public health challenge posed by histoplasmosis, particularly in HIV-infected populations.
• To advocate for improved diagnostics and treatment accessibility to reduce mortality.
• To underscore the importance of addressing histoplasmosis as a neglected tropical disease.

Main Methods:

• Review of global epidemiology and clinical impact of histoplasmosis.
• Analysis of initiatives and policy changes promoting diagnostics and treatment.
• Examination of WHO Essential Diagnostics and Medicines Lists inclusion.

Main Results:

• The Histoplasma antigen test is now on the WHO Essential Diagnostics List.
• Key antifungal treatments (amphotericin B, itraconazole) are on the WHO Essential Medicine List.
• The Manaus Declaration advocates for universal access to testing and treatment by 2025.

Conclusions:

• Histoplasmosis remains a major clinical and public health concern, especially in hyperendemic regions.
• Reducing HIV-associated mortality requires addressing disseminated histoplasmosis through advocacy and awareness.
• Universal access to rapid diagnostics and essential antifungal agents is crucial for effective management.